ADVERTISEMENT
Glenmark Pharma’s FabiFlu Booster Is Waning
A three-quarter growth run at Glenmark maybe coming to an end as FabiFlu now faces many more competitors.
27 Nov 2020, 02:52 PM IST
A three-quarter growth run at Glenmark Pharmaceuticals Ltd. may be coming to an end, said analysts, as its FabiFlu now faces many more competitors.As the first company in India to receive regulatory approval for oral antiviral Favipiravir (sold under the FabiFlu brand) in June 2020, for the treatment of mild to moderate Covid-19, Glenmark notched up an impressive 85-90% market share by September.The drug boosted Glenmark to become on...
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Members-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories
20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Members-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT